A-Raf (encoded by the ARAF gene) is a serine/threonine protein kinase belonging to the RAF family (along with BRAF and RAF1/C-Raf). A-Raf functions as a component of the RAS-RAF-MEK-ERK/MAPK signaling cascade, a central pathway regulating cell proliferation, differentiation, survival, and neuronal function. [1]
| A-Raf Protein | |
|---|---|
| Protein Name | A-Raf (Serine/threonine-protein kinase A-Raf) |
| Gene Symbol | ARAF |
| Gene | [ARAF Gene](/genes/araf) |
| UniProt ID | [P04003](https://www.uniprot.org/uniprot/P04003) |
| Protein Family | RAF family, MAP3K |
| Molecular Weight | 67.6 kDa |
| Length | 606 amino acids |
| Subcellular Location | Cytoplasm, cell membrane (associated) |
| Expression | Ubiquitous, highest in brain, heart, lung |
A-Raf contains three conserved regions (CR) characteristic of RAF kinases: [1:1]
| Domain | Position | Function |
|---|---|---|
| CR1 (Regulatory) | 1-131 aa | Contains cysteine-rich domain (C1) that binds DAG/PMA and GTPase-binding domain (GBA) for RAS interaction |
| CR2 (Rregion) | 132-207 aa | Serine-rich hinge region; contains inhibitory phosphorylation sites |
| CR3 (Kinase) | 208-606 aa | Catalytic kinase domain with ATP-binding and substrate-binding pockets |
The kinase domain of A-Raf adopts the typical bilobal fold of protein kinases, with the ATP-binding pocket in the N-lobe and the substrate-binding groove in the C-lobe. However, A-Raf has relatively weak kinase activity compared to BRAF and RAF1, and its activation often requires heterodimerization with other RAF family members. [2]
A-Raf activation follows the canonical RAF activation pathway:
A-Raf functions as a MAP3K (MAP kinase kinase kinase) within the RAS-RAF-MEK-ERK cascade: [3]
RAS-GTP → RAF kinases (A-Raf/BRAF/RAF1) → MEK1/2 → ERK1/2 → Transcription factors
This pathway controls:
In the central nervous system, A-Raf and other RAF kinases play critical roles: [4]
A-Raf has somewhat distinct functions from BRAF and RAF1, with more tissue-specific expression patterns and weaker transforming potential. This suggests specialized roles in specific cellular contexts.
ERK/MAPK dysregulation is well-documented in Alzheimer's disease: [5] [6]
A-Raf specifically contributes to:
MAPK signaling alterations are also implicated in PD: [7]
The role of A-Raf specifically in PD remains less characterized than BRAF or RAF1, but it likely contributes to the overall dysregulation of MAPK signaling observed in PD brains.
A-Raf interacts with multiple cellular proteins:
| Interactor | Interaction Type | Functional Relevance |
|---|---|---|
| RAS proteins | Direct binding | Membrane recruitment and activation |
| BRAF/RAF1 | Heterodimerization | Trans-activation, expanded signaling |
| MEK1/2 | Phosphorylation | Direct substrate |
| 14-3-3 proteins | Binding | Regulatory (inhibitory) |
| Hsp90 | Chaperone binding | Stability and maturation |
| p62/SQSTM1 | Autophagy receptor | Selective autophagy |
| PTEN | Interaction | Cross-talk with PI3K/AKT |
Direct targeting of RAF kinases for neurodegeneration is complex: [8]
While no A-Raf-specific therapies exist for neurodegenerative diseases, understanding A-Raf function provides insight into the broader MAPK dysregulation observed in these conditions.
A-Raf is a serine/threonine kinase that contributes to RAS-RAF-MEK-ERK signaling in neurons and other cell types. While less studied than BRAF and RAF1 in neurodegeneration, A-Raf participates in the MAPK pathway dysregulation observed in Alzheimer's disease, Parkinson's disease, and related conditions. The RAF-MEK-ERK cascade influences tau pathology, synaptic dysfunction, and neuronal survival, making it a topic of interest for understanding neurodegenerative disease mechanisms.
Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacol Rev. 2020. ↩︎ ↩︎
Karakhanova S, Meijer J, Herde M, et al. A-Raf kinase: a key regulator of cell growth and differentiation. J Mol Signal. 2018. ↩︎
Mendoza MC, Er EE, Blenis J. The Ras-RAF-MEK-ERK pathway in cell proliferation, survival and differentiation. Cold Spring Harb Perspect Biol. 2021. ↩︎
Yin Z, Xu J, Zhou C. RAF kinases in neural development and neurological disorders. Front Cell Neurosci. 2019. ↩︎
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta Mol Basis Dis. 2020. ↩︎
Liu Y, Yang J, Wang L. ERK/MAPK activation and tau pathology in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2021. ↩︎
Song J, Kim J, Lee S. Dysregulation of MAPK signaling in Parkinson's disease models. J Parkinsons Dis. 2023. ↩︎
Patel AJ, Lazidou F, Knott S. Targeting RAF kinases for neuroprotection: opportunities and challenges. Pharmacol Res. 2023. ↩︎